191 related articles for article (PubMed ID: 24080888)
1. Protection of Enterococcus faecalis in mixed cultures with carbapenemase-producing Escherichia coli and Bacteroide fragilis: effect of the bacterial load.
Sevillano D; Aguilar L; Alou L; Giménez MJ; Cafini F; González N; Prieto J
Rev Esp Quimioter; 2013 Sep; 26(3):220-5. PubMed ID: 24080888
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of trovafloxacin against Bacteroides fragilis in mixed culture with either Escherichia coli or a vancomycin- resistant strain of Enterococcus faecium determined by an anaerobic time-kill technique.
Stearne LE; Kooi C; Goessens WH; Bakker-Woudenberg IA; Gyssens IC
Antimicrob Agents Chemother; 2001 Jan; 45(1):243-51. PubMed ID: 11120973
[TBL] [Abstract][Full Text] [Related]
3. Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria.
Sevillano D; Aguilar L; Alou L; Giménez MJ; González N; Torrico M; Cafini F; Garcia-Rey C; Garcia-Escribano N; Prieto J
Int J Antimicrob Agents; 2010 Aug; 36(2):137-44. PubMed ID: 20462741
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
Cha R
Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108
[TBL] [Abstract][Full Text] [Related]
5. Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model.
Zhanel GG; Baudry PJ; Tailor F; Cox L; Hoban DJ; Karlowsky JA
J Antimicrob Chemother; 2009 Oct; 64(4):824-8. PubMed ID: 19643776
[TBL] [Abstract][Full Text] [Related]
6. In vitro bactericidal activity of piperacillin, gentamicin, and metronidazole in a mixed model containing Escherichia coli, Enterococcus faecalis, and Bacteroides fragilis.
Pendland SL; Jung R; Messick CR; Schriever CA; Patka J
Diagn Microbiol Infect Dis; 2002 Jun; 43(2):149-56. PubMed ID: 12088623
[TBL] [Abstract][Full Text] [Related]
7. Time-kill synergy tests of tigecycline combined with imipenem, amikacin, and ciprofloxacin against clinical isolates of multidrug-resistant Klebsiella pneumoniae and Escherichia coli.
Yim H; Woo H; Song W; Park MJ; Kim HS; Lee KM; Hur J; Park MS
Ann Clin Lab Sci; 2011; 41(1):39-43. PubMed ID: 21325253
[TBL] [Abstract][Full Text] [Related]
8. Efficacies of colistin and tigecycline in mice with experimental pneumonia due to NDM-1-producing strains of Klebsiella pneumoniae and Escherichia coli.
Docobo-Pérez F; Nordmann P; Domínguez-Herrera J; López-Rojas R; Smani Y; Poirel L; Pachón J
Int J Antimicrob Agents; 2012 Mar; 39(3):251-4. PubMed ID: 22154856
[TBL] [Abstract][Full Text] [Related]
9. Activity of moxifloxacin, imipenem, and ertapenem against Escherichia coli, Enterobacter cloacae, Enterococcus faecalis, and Bacteroides fragilis in monocultures and mixed cultures in an in vitro pharmacokinetic/pharmacodynamic model simulating concentrations in the human pancreas.
Schubert S; Dalhoff A
Antimicrob Agents Chemother; 2012 Dec; 56(12):6434-6. PubMed ID: 23070164
[TBL] [Abstract][Full Text] [Related]
10. Effect of inoculum size and medium on activity of seven antimicrobial agents against Bacteroides fragilis strains.
Wexler HM; Reeves D; Finegold SM
Clin Ther; 1989; 11(6):828-33. PubMed ID: 2611824
[TBL] [Abstract][Full Text] [Related]
11. Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.
Hermsen ED; Hovde LB; Sprandel KA; Rodvold KA; Rotschafer JC
Antimicrob Agents Chemother; 2005 Feb; 49(2):685-9. PubMed ID: 15673752
[TBL] [Abstract][Full Text] [Related]
12. In vitro interference of tigecycline at subinhibitory concentrations on biofilm development by Enterococcus faecalis.
Maestre JR; Aguilar L; Mateo M; Giménez MJ; Méndez ML; Alou L; Granizo JJ; Prieto J
J Antimicrob Chemother; 2012 May; 67(5):1155-8. PubMed ID: 22323499
[TBL] [Abstract][Full Text] [Related]
13. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.
Pournaras S; Vrioni G; Neou E; Dendrinos J; Dimitroulia E; Poulou A; Tsakris A
Int J Antimicrob Agents; 2011 Mar; 37(3):244-7. PubMed ID: 21236643
[TBL] [Abstract][Full Text] [Related]
14. In vitro effect of physiological concentrations of human albumin on the antibacterial activity of tigecycline.
Alou L; Giménez MJ; Cafini F; Aguilar L; Sevillano D; González N; Torrico M; Prieto J; García-Rey C; García-Escribano N
J Antimicrob Chemother; 2009 Dec; 64(6):1230-3. PubMed ID: 19837715
[TBL] [Abstract][Full Text] [Related]
15. Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula.
Maglio D; Ong C; Banevicius MA; Geng Q; Nightingale CH; Nicolau DP
Antimicrob Agents Chemother; 2004 Jun; 48(6):1941-7. PubMed ID: 15155182
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility trends of Bacteroides fragilis group and characterisation of carbapenemase-producing strains by automated REP-PCR and MALDI TOF.
Treviño M; Areses P; Peñalver MD; Cortizo S; Pardo F; del Molino ML; García-Riestra C; Hernández M; Llovo J; Regueiro BJ
Anaerobe; 2012 Feb; 18(1):37-43. PubMed ID: 22261518
[TBL] [Abstract][Full Text] [Related]
17. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.
Burgess DS; Hall RG
Diagn Microbiol Infect Dis; 2004 May; 49(1):41-6. PubMed ID: 15135499
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of tigecycline: MICs, MBCs, time-kill curves and post-antibiotic effect.
Noviello S; Ianniello F; Leone S; Fiore M; Esposito S
J Chemother; 2008 Oct; 20(5):577-80. PubMed ID: 19028619
[TBL] [Abstract][Full Text] [Related]
19. Ampicillin and ampicillin-sulbactam dilution tests with mixed cultures of Bacteroides fragilis, Escherichia coli and Enterococcus.
Heilmann F
Infection; 1993; 21(3):187-90. PubMed ID: 8365818
[TBL] [Abstract][Full Text] [Related]
20. Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolates.
Arias CA; Singh KV; Panesso D; Murray BE
Antimicrob Agents Chemother; 2007 Jun; 51(6):2043-7. PubMed ID: 17438057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
